Nadine Sebban
The lethal plague, which is brought on by the bacteria Yersinia pestis, continues to be a problem for global public health. The bubonic plague, septicemic plague and pulmonary plague are the three primary clinical types. The signs and symptoms of all three kinds all emerge out of nowhere and worsen extremely quickly. Early antibiotic treatment is crucial for fighting the illness. Several families of antibiotics, including tetracyclines, fluoroquinolones, aminoglycosides, sulfonamides, chloramphenicol, rifamycin and beta-lactams, have shown effectiveness in various animal models and are active in vitro against the majority of Y. pestis strains. There have been a few documented inconsistencies, though. As a result, various medications have been licenced or suggested for use in treating or preventing disease. Currently, only monotherapy is advised; case reports or preclinical studies have demonstrated no benefits from combined medication. apprehensions regarding the rise of drug-resistant New families of antibiotics and other treatments have been created as a result of strains of Y. pestis (e.g., LpxC inhibitors, cationic peptides, antivirulence drugs, predatory bacteria, phages, immunotherapy, host-directed therapy and nutritional immunity). It is challenging to predict which of the currently developed medicines or treatments will be most efficient for a certain form of plague. This results from inconsistent data from case reports, a lack of standardisation in preclinical studies and a dearth of clinical trials to date.
この記事をシェアする
English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi 